Clinical Trial

Disease: Beta-Thalassemia, BT, (NCT04211480)

Disease info:

Beta-thalassemia is a group of blood disorders characterised by a reduction in the production of haemoglobin. Haemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

Haemoglobin is encoded by genes that encode the building blocks of the haemoglobin protein. Mutations in these genes can produce abnormal haemoglobins leading to a family of conditions termed "haemoglobinopathies". Abnormal haemoglobin appears in one of three basic circumstances:

  1. Structural defects in the haemoglobin molecule. Alterations in the gene for one of the two haemoglobin subunit chains, alpha (a) or beta (b), are called mutations. Often, mutations change a single amino acid building block in the subunit. Most commonly the change is innocuous, perturbing neither the structure nor function of the haemoglobin molecule. Occasionally, alteration of a single amino acid dramatically disturbs the behaviour of the haemoglobin molecule and produces a disease state. Sickle haemoglobin exemplifies this phenomenon.
  2. Diminished production of one of the two subunits of the haemoglobin molecule. Mutations that produce this condition are termed "thalassemias." Equal numbers of haemoglobin alpha and beta chains are necessary for normal function. Haemoglobin chain imbalance damages and destroys red cells thereby producing anaemia. Although there is a dearth of the affected haemoglobin subunit, with most thalassemias the few subunits synthesised are structurally normal.
  3. Abnormal associations of otherwise normal subunits. A single subunit of the alpha chain (from the a-globin locus) and a single subunit from the b-globin locus combine to produce a normal haemoglobin dimer. With severe a-thalassemia, the b-globin subunits begin to associate into groups of four (tetramers) due to the paucity of potential a-chain partners. These tetramers of b-globin subunits are functionally inactive and do not transport oxygen. No comparable tetramers of alpha globin subunits form with severe beta-thalassemia. Alpha subunits are rapidly degraded in the absence of a partner from the beta-globin gene cluster (gamma, delta, beta globin subunits).

In individuals suffering from beta-thalassemia, low levels of haemoglobin lead to a lack of oxygen in many parts of the body. People with beta-thalassemia are at an increased risk of developing abnormal blood clots.

Beta-thalassemia is classified into two types depending on symptom severity. Transfusion-dependent thalassemia, also known as thalassemia major, is the more severe, while thalassemia intermedia is less severe-

Frequency:
Annually, approximately 1 in 100,000 cases are diagnosed worldwide. Beta-thalassaemia occurs most frequently in people from Mediterranean countries, North Africa, the Middle East, India, China and South East Asia.
Official title:
An Open Label Trial of Evaluation of the Safety and Efficacy of Treatment With γ-globin Reactivated Autologous Hematopoietic Stem Cells in Subjects With β-thalassemia Major
Who:

Principal Investigator: Bin Fu, Prof., Xiangya Hospital Central University  

Partners:

Xiangya Hospital of Central South University

Chinese PLA 923 Hospital

Locations:

China, Shanghai

Shanghai Bioray Laboratories Inc., Shanghai, Shanghai, China, 200241

Study start:
Apr. 1, 2020
Enrollment:
6 participants
Gene editing method:
CRISPR-Cas9
Gene:
Hemoglobin Subunit Gamma 1 (HBG1)
Delivery method:
Electroporation - Ex-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active not recruiting

Description

This study aims to evaluate the safety and efficacy of the treatment with γ-globin reactivated autologous haematopoietic stem cells (HSCs) in subjects with β-thalassemia major.

Manufacturing of γ-globin reactivated autologous haematopoietic stem cells will be performed using CRISPR-Cas9 gene editing and each subject will accept one dose of γ-globin reactivated autologous HSCs throughout the 1 year duration of the study. Subjects who enroll in this study will be asked to participate in a subsequent long-term follow up study that will monitor the safety and efficacy of the treatment they receive for up to 15 years post-transplant.

Last updated: Dec. 28, 2023
close
Search CRISPR Medicine